Neonc Technologies CSO Thomas Chen buys $192,899 in stock

Thomas C. Chen, Chief Scientific Officer and 10% owner of NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), acquired approximately $192,899 worth of the company's common stock in April and August 2026. The purchases were made through individual transactions across multiple price points, with a weighted average cost ranging from $3.8477 to $5.1677 per share.

In April, Chen indirectly bought 948 shares through an IRA at a weighted average price of $5.1677 per share, with each share priced between $5.165 and $5.1722. Later that month, he acquired an additional 10,000 shares via a Defined Benefit Plan at $4.80 per share. In August, Chen made two direct purchases: on August 14, he bought 33,787 shares at a weighted average price of $3.8477 per share, ranging from $3.2299 to $4.0993 per share; and on August 17, he purchased 2,472 shares at a weighted average price of $4.0445 per share, between $4.04 and $4.1699 per share.

These direct holdings, including shares belonging to family members, are considered to be held dispassionately by Chen, except for his financial interest. Beyond his direct and indirect holdings, Chen has disclosed beneficial ownership of other shares through various entities, totalling 1,564,114 shares. NeOnc Technologies has also recently reported significant clinical trial progress, including positive topline results from a Phase 2a study of its intranasal treatment NEO100 for recurrent IDH1-mutant high-grade glioma, which showed a 48.9% progression-free survival rate, exceeding standard care benchmarks.

Additionally, NeOnc received Investigational New Drug approval from the Department of Health - Abu Dhabi for both NEO100 and NEO212, enabling further clinical trials in brain cancer treatment.